The decrease in ALT and AST levels (Figure 7O and P) and improvement in liver histology (Figure S5F) indicate that hADP‐Ucp1 OE treatment can significantly improve obesity induced metabolic dysfunction associated fatty liver disease (MASLD) in mice. This evidence concerns the gene UCP1 and metabolic dysfunction-associated steatotic liver disease.